Sernova Corp (Sernova) is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organ-like environment for the long-term survival and function of insulin producing islets for the treatment of diabetes. Sernova uses proprietary local immune protection technologies that protect therapeutic cells within the Cell Pouch from the attack of immune system. Its major pipeline products include human donor islets, microencapsulated islets; microencapsulated stem cell derived cells; corrected patient cells; allograft immune protected cells; and autograft thyroid cells. The company’s product portfolio addresses metabolic diseases such as insulin dependent diabetes, thyroid problems, blood disorders such as hemophilia A and other diseases. Sernova is headquartered in London, Ontario, Canada.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Sernova Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Sernova Corp Company Overview
Sernova Corp Company Snapshot
Sernova Corp Pipeline Products and Ongoing Clinical Trials Overview
Sernova Corp – Pipeline Analysis Overview
Business Description
Sernova Corp - Key Facts
Sernova Corp - Major Products and Services
Sernova Corp Pipeline Products by Development Stage
Sernova Corp Ongoing Clinical Trials by Trial Status
Sernova Corp Pipeline Products Overview
Cell Pouch System - Hemophilia
Cell Pouch System - Hemophilia Product Overview
Cell Pouch System - Hemophilia Allograft Immune Protected Cells
Nov 27, 2023: Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for Its Hemophilia a Program from FDA
Oct 30, 2023: Sernova Announces New Advancements of Conformal Coating Technology in Combination With the Cell Pouch System At the 2023 IPITA-IXA-CTRMS Joint Congress
Oct 27, 2023: Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
Oct 11, 2023: Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
Sep 29, 2023: Sernova Presents Compelling New Data on the Cell Pouch System as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting
Sep 14, 2023: Slone Partners Places Cynthia Pussinen as Chief Executive Officer and Member of the Board of Directors at Sernova Corporation
Sep 13, 2023: Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
Sep 07, 2023: Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
Table 20: Cell Pouch System - Type 1 Diabetes Mellitus - Product Status
Table 21: Cell Pouch System - Type 1 Diabetes Mellitus - Product Description
Table 22: Cell Pouch System - Type 1 Diabetes Mellitus - A Phase I/II First-in-human of Cell Pouch Device for the Treatment of Patients with T1D and Severe Hypoglycemia
Table 23: Cell Pouch System - Type 1 Diabetes Mellitus - A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch for Clinical Islet Transplantation
Table 24: Sernova Corp, Key Employees
Table 25: Sernova Corp, Key Employee Biographies
Table 26: Glossary
List of Figures
Figure 1: Sernova Corp Pipeline Products by Equipment Type
Figure 2: Sernova Corp Pipeline Products by Development Stage
Figure 3: Sernova Corp Ongoing Clinical Trials by Trial Status